<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Intraoperative hemodynamic management of aortic or mitral valve disease in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Intraoperative hemodynamic management of aortic or mitral valve disease in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Intraoperative hemodynamic management of aortic or mitral valve disease in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Manuel L Fontes, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan B Mark, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patricia A Pellikka, MD, FACC, FAHA, FASE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Nussmeier, MD, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1457915750">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk for development of valvular heart disease (VHD) increases with age, and more than 13 percent of adults ≥75 years old have moderate or severe disease of one or more cardiac valves  (
         <a class="graphic graphic_table graphicRef77504" href="/z/d/graphic/77504.html" rel="external">
          table 1
         </a>
         ). The most common lesions are aortic stenosis (AS) due to degeneration and calcification of the valve in older adults or early calcification of a congenital bicuspid aortic valve, and mitral regurgitation (MR) due to primary causes (eg, intrinsic disease of the mitral leaflets or subvalvular apparatus) or secondary functional causes (eg, cardiomyopathy with left ventricular enlargement and annular dilatation or ischemic [postinfarction] MR)  (
         <a class="graphic graphic_figure graphicRef108930" href="/z/d/graphic/108930.html" rel="external">
          figure 1
         </a>
         ). Patients often have a combination of stenosis and regurgitation in a single cardiac valve, or disease of more than one valve. (See
         <a class="medical medical_review" href="/z/d/html/8147.html" rel="external">
          "Valvular heart disease in older adults"
         </a>
         .)
        </p>
        <p>
         This topic will discuss perioperative hemodynamic management for patients with aortic or mitral valve lesions. Among patients with VHD, patients with severe valve lesions, particularly those with severe AS, are at greatest risk for adverse perioperative cardiovascular events. Mild cardiac valve disease does not typically contribute to hemodynamic instability. Patients with moderate VHD can be at significant risk for adverse events if there are combined valve lesions (eg, concomitant AS and aortic regurgitation [AR]), or concomitant heart failure or ischemic heart disease.
        </p>
        <p>
         Additional anesthetic considerations for noncardiac surgery in patients with these comorbidities are addressed separately. (See
         <a class="medical medical_review" href="/z/d/html/91654.html" rel="external">
          "Intraoperative management for noncardiac surgery in patients with heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease"
         </a>
         .)
        </p>
        <p>
         Other anesthetic considerations for patients with aortic or mitral valve disease who are undergoing cardiac or noncardiac surgery are discussed in separate topics.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/91483.html" rel="external">
          "Anesthesia for cardiac valve surgery"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/93514.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with aortic or mitral valve disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">
          "Anesthesia for labor and delivery in high-risk heart disease: Specific lesions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3133355183">
         <span class="h1">
          AORTIC STENOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe aortic stenosis (AS) poses substantial risks for maintenance of perioperative hemodynamic stability [
         <a href="#rid1">
          1
         </a>
         ]. Key points for perioperative hemodynamic management of patients with AS are described below and summarized in the table  (
         <a class="graphic graphic_table graphicRef108941" href="/z/d/graphic/108941.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H942577996">
         <span class="h2">
          Heart rhythm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintenance of sinus rhythm (SR) is particularly important in patients with AS because filling of the hypertrophic noncompliant left ventricle (LV) depends significantly on left atrial contraction (atrial "kick") during end-diastole. Loss of atrioventricular (AV) synchrony may result in severe hypotension. Examples include supraventricular tachyarrhythmia (SVT) such as atrial fibrillation (AF) or flutter, or AV dissociation such as junctional rhythm or ventricular pacing. Hypotension occurs due to markedly reduced LV filling, which reduces stroke volume (SV) and cardiac output (CO).
        </p>
        <p>
         New onset of AF or other SVT is rapidly treated to restore SR, as well as to control ventricular rate. In a hemodynamically stable patient, treatment with short-acting drugs such as
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         or
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         may be adequate. In a hemodynamically unstable patient with severe hypotension or evidence of cardiogenic shock, synchronized cardioversion may be necessary to restore SR. During preparations for urgent cardioversion, systemic blood pressure (BP) is maintained with vasoconstrictors (eg,
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         or
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">
          "Arrhythmias during anesthesia", section on 'Other narrow QRS complex atrial tachyarrhythmias'
         </a>
         .)
        </p>
        <p>
         A junctional rhythm with loss of atrial kick may occur during administration of a volatile inhalation agent or other anesthetics [
         <a href="#rid2">
          2-5
         </a>
         ]. Attempts to restore SR include decreasing the dose of inhalation anesthetic while maintaining systemic BP with administration of
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         .
        </p>
        <p>
         If severe hypotension persists despite treatment of the arrhythmia in a patient undergoing cardiac surgery, cardiopulmonary bypass is initiated as rapidly as possible. Nonperfusing arrhythmias are particularly dangerous in patients with AS due to limited effectiveness of chest compressions during resuscitation efforts. Perfusion to the brain and other end-organs may be inadequate because the stenotic aortic valve obstructs LV outflow.
        </p>
        <p class="headingAnchor" id="H63775614">
         <span class="h2">
          Heart rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintain heart rate (HR) in the low to normal range (eg, 60 to 80 beats per minute [bpm]) in patients with AS; the target range may be adjusted based upon the patient's baseline HR. Tachycardia may compromise LV filling or lead to myocardial ischemia, while bradycardia may result in inadequate CO with compromise of vital organ perfusion.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention and management of tachycardia
         </strong>
         – Prevent tachycardia by ensuring adequate volume status and adequate depth of anesthesia and perioperative analgesia. A rapid HR results in inadequate oxygen delivery to the hypertrophied myocardium due to the decrease in diastolic filling time  (
         <a class="graphic graphic_figure graphicRef94174" href="/z/d/graphic/94174.html" rel="external">
          figure 2
         </a>
         ). Myocardial ischemia can occur, particularly in patients with coexisting coronary artery disease  (
         <a class="graphic graphic_table graphicRef91907" href="/z/d/graphic/91907.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Sinus tachycardia due to noxious surgical stimuli is treated by increasing anesthetic depth (eg, increasing concentration of volatile or intravenous (IV) anesthetic agents or administration of additional opioid). If other causes of tachycardia such as hypovolemia and anemia have been excluded and tachycardia persists, an IV beta blocker (eg,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         as a bolus dose of 20 to 30 mg and/or by continuous infusion, or
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         in 2.5 to 5 mg increments [or lower incremental doses for small or frail patients]) may be administered to control HR. (See
         <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">
          "Arrhythmias during anesthesia", section on 'Sinus tachycardia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As noted above, if tachycardia is due to AF with rapid ventricular response, ventricular rate control should be achieved, whether or not SR is restored. (See
         <a class="local">
          'Heart rhythm'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">
          "Arrhythmias during anesthesia", section on 'Other narrow QRS complex atrial tachyarrhythmias'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of bradycardia
         </strong>
         – Treat bradycardia by administering IV bolus doses of
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         5 to 10 mg and/or small doses of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         (eg, 4 to 10 mcg). Use of anticholinergic agent (
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         0.2 mg or
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         0.4 mg) can be ineffective and/or have inconsistent responses in patients with AS since patients with AS are at risk for conduction disease below the AV node [
         <a href="#rid6">
          6
         </a>
         ]. Causes should be identified and treated  (
         <a class="graphic graphic_table graphicRef127098" href="/z/d/graphic/127098.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">
          "Arrhythmias during anesthesia", section on 'Bradyarrhythmias'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">
          "Arrhythmias during anesthesia", section on 'Pharmacologic treatment of bradycardia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Severe bradycardia typically results in inadequate CO with hypotension in patients with severe AS because they cannot compensate for low HR by increasing SV through the stenotic aortic valve. For hemodynamically unstable patients, temporizing measures include continuous infusion of an adrenergic agonist (eg,
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         ) or temporary transcutaneous pacing. Patients with recurrent or severe bradycardia causing hemodynamic instability may require transvenous pacing via insertion of a pacing catheter inserted into a central venous catheter or a pulmonary artery catheter with pacing capability. (See
         <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">
          "Arrhythmias during anesthesia", section on 'Pharmacologic treatment of bradycardia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">
          "Arrhythmias during anesthesia", section on 'Temporary pacing options'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Expert cardiology (ie, electrophysiology) consultation is sought to assist with management of persistent or recurrent severe bradycardia and the potential need for permanent pacing.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H397711629">
         <span class="h2">
          Preload (intravascular volume)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintain adequate intravascular volume (ie, preload) to preserve adequate SV and CO, while avoiding volume overload.
        </p>
        <p>
         Hypovolemia should be promptly identified and treated. Fluid boluses are titrated according to clinical assessment of volume status and the patient's hemodynamic response. If an intra-arterial catheter and/or transesophageal echocardiography (TEE) probe have been inserted, we employ a goal-directed approach to fluid therapy, using dynamic parameters to assess intravascular volume status, guide fluid administration during treatment of hypovolemia, and avoid hypervolemia and pulmonary edema  (
         <a class="graphic graphic_figure graphicRef86275" href="/z/d/graphic/86275.html" rel="external">
          figure 3
         </a>
         and
         <a class="graphic graphic_movie graphicRef104149" href="/z/d/graphic/104149.html" rel="external">
          movie 1
         </a>
         ). As a temporary measure, changing patient position to mild Trendelenburg may augment preload in patients with hypotension. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Dynamic parameters to assess volume responsiveness'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3266256862">
         <span class="h2">
          Afterload (systemic vascular resistance)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintain systolic BP at &gt;100 mmHg, mean arterial pressure (MAP) &gt;70 mmHg, or both within 20 percent of baseline. Although afterload is chronically increased in patients with AS, sudden reductions in systemic vascular resistance (SVR) may result in decreased diastolic BP, with decreased coronary perfusion and consequent myocardial ischemia.
        </p>
        <p>
         Hypotension should be prevented and/or treated promptly. An alpha-adrenergic vasoconstrictor such as
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         may be administered as bolus doses of 40 to 100 mcg or by continuous infusion. If phenylephrine is ineffective,
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         or
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         may be administered  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         ). These vasoconstrictors increase SVR without the chronotropic side effects associated with sympathomimetic vasoactive agents such as
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         . If hypovolemia is suspected, fluids are also administered as described above. (See
         <a class="local">
          'Preload (intravascular volume)'
         </a>
         above.)
        </p>
        <p>
         Hypertension may also aggravate ischemia should also be prevented by ensuring adequate depth of anesthesia and perioperative analgesia. Severe or persistent hypertension should be controlled. For hypertension accompanied by an increased HR, a beta blocker may be administered (eg,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         in small bolus doses of 20 to 30 mg and/or by continuous infusion, or
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         in 2.5 to 5 mg increments [or lower incremental doses for small or frail patients])  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ). Other antihypertensive agents should be administered with caution (ie, titrated slowly in incremental doses) as need for adequate BP control. (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3973692982">
         <span class="h2">
          Contractility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avoid doses of anesthetic agents that might cause significant depression of myocardial contractility (eg, high doses of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or volatile inhalation anesthetic agents). Although biventricular function is typically preserved in patients with moderate to severe AS, LV ejection fraction may be lower than normal (due to the afterload excess imposed by the stenotic valve rather than intrinsic LV contractile dysfunction) [
         <a href="#rid7">
          7-9
         </a>
         ]. If inotropic support is needed,
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         is preferred unless there is coexisting bradycardia  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         ). Other agents with stronger inotropy and chronotropy (eg,
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ) may cause tachycardia and increase myocardial oxygen demand leading to myocardial ischemia.
        </p>
        <p class="headingAnchor" id="H1252610">
         <span class="h1">
          MITRAL STENOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Key points for perioperative hemodynamic management of patients with mitral stenosis (MS) are described below and summarized in the table  (
         <a class="graphic graphic_table graphicRef108960" href="/z/d/graphic/108960.html" rel="external">
          table 7
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1541554942">
         <span class="h2">
          Heart rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintain a slow to normal heart rate (HR) at 50 to 70 beats per minute (bpm).
        </p>
        <p>
         Avoid tachycardia. Any tachyarrhythmia (eg, sinus tachycardia or atrial fibrillation [AF] with rapid ventricular response) can result in severe hypotension and pulmonary edema due to shortening of the diastolic period  (
         <a class="graphic graphic_figure graphicRef94174" href="/z/d/graphic/94174.html" rel="external">
          figure 2
         </a>
         ), with inadequate time for blood to flow from the left atrium (LA) into the left ventricle (LV) through the stenotic mitral valve. This decrease in LV filling, stroke volume (SV), and cardiac output (CO) leads to hypotension, while the increase in LA pressure leads to pulmonary edema.
        </p>
        <p>
         Although a relatively slow HR is optimal, CO is partially dependent on maintenance of an adequate HR. Severe bradycardia should be avoided as the limited flow across the stenotic mitral valve limits LV filling and SV. Pharmacologic agents for severe bradycardia associated with hypotension include
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         or
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">
          "Arrhythmias during anesthesia", section on 'Pharmacologic treatment of bradycardia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H417593867">
         <span class="h2">
          Heart rhythm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although sinus rhythm (SR) is preferred, many patients with MS have chronic AF because of left atrial dilation. The presence of AF is less important for patients with MS than those with aortic stenosis (AS) because there is less dependence on end-diastolic LA contraction (atrial "kick") to achieve adequate LV filling. However, regardless of rhythm, the ventricular rate must remain well controlled. Thus, onset of AF with rapid ventricular response warrants urgent rate control. Clinical settings in which urgent or emergency cardioversion to SR may be required include evidence of acute myocardial ischemia, evidence of organ hypoperfusion or shock, severe heart failure, and severe refractory hypotension despite therapies including volume repletion and attempted rate control. The risks and benefits of cardioversion should be weighed since patients with significant MS who are cardioverted to SR may soon revert to AF. Also, patients with MS and AF are at risk for thromboembolism. Thus, evaluation with transesophageal echocardiography (TEE) to exclude left atrial thrombus is generally necessary prior to urgent intraoperative cardioversion, even if anticoagulants have been chronically administered. (See
         <a class="medical medical_review" href="/z/d/html/91483.html" rel="external">
          "Anesthesia for cardiac valve surgery", section on 'Prebypass TEE assessment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113847.html" rel="external">
          "Atrial fibrillation in patients undergoing noncardiac surgery", section on 'Intraoperative atrial fibrillation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8139.html" rel="external">
          "Rheumatic mitral stenosis: Overview of management", section on 'Prevention of thromboembolism'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8139.html" rel="external">
          "Rheumatic mitral stenosis: Overview of management", section on 'Management of atrial fibrillation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3716449944">
         <span class="h2">
          Preload (intravascular volume)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintain intravascular volume (ie, preload) to preserve adequate SV and CO.
        </p>
        <p>
         Fluid boluses are titrated according to clinical assessment of intravascular volume status, and the hemodynamic response to each incremental bolus of 100 to 250 mL is assessed. Because of obstructed flow from the LA to the LV, aggressive fluid administration may result in increased LA pressure and pulmonary congestion. If an intra-arterial catheter and/or TEE probe have been inserted, we employ a goal-directed approach to fluid therapy  (
         <a class="graphic graphic_figure graphicRef86275" href="/z/d/graphic/86275.html" rel="external">
          figure 3
         </a>
         and
         <a class="graphic graphic_movie graphicRef104149" href="/z/d/graphic/104149.html" rel="external">
          movie 1
         </a>
         ), similar to management of AS. (See
         <a class="local">
          'Preload (intravascular volume)'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Dynamic parameters to assess volume responsiveness'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3476699568">
         <span class="h2">
          Afterload (systemic vascular resistance)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintain systolic blood pressure (BP) &gt;100 mmHg, mean arterial pressure (MAP) &gt;70 mmHg, or both within 20 percent of baseline. Maintenance of systemic vascular resistance (SVR) is important since the presence of MS interferes with normal compensatory responses to hypotension (ie, SV cannot be substantially increased and a slow HR must be maintained).
        </p>
        <p>
         When hypotension is presumed to be caused by decreased SVR, it should be treated with an alpha-adrenergic vasoconstrictor such as
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         , administered as bolus doses of 40 to 100 mcg or as an infusion  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         ). If phenylephrine is ineffective, a
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         or
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         infusion may be administered.
        </p>
        <p>
         It is rarely necessary to treat hypertension, since the obstruction to transmitral flow limits CO and usually prevents development of high BP.
        </p>
        <p class="headingAnchor" id="H1554203454">
         <span class="h2">
          Contractility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avoid doses of drugs that might cause significant depression of LV or right ventricular (RV) contractility (eg, high doses of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or volatile inhalation anesthetic agents).
        </p>
        <p>
         Although most patients with advanced MS have preserved LV systolic function, RV function is often impaired. Avoiding further RV depression is particularly important in patients with significant pulmonary hypertension (PH). If inotropic support is necessary, the inodilator
         <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">
          milrinone
         </a>
         is typically selected because it increases SV via a combination of peripheral dilation and enhanced contractility and has pulmonary vasodilating effects  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         ). However, a low-dose
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         infusion is a reasonable alternative for hypotensive patients.
        </p>
        <p class="headingAnchor" id="H1294874973">
         <span class="h2">
          Pulmonary vascular resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avoid hypoxemia, hypercarbia, and metabolic acidosis, which increase PVR. These are particularly detrimental in patients with severe MS because exacerbation of pre-existing PH may cause acute RV failure.
        </p>
        <p class="headingAnchor" id="H3091494728">
         <span class="h1">
          AORTIC REGURGITATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Key points for perioperative hemodynamic management of patients with aortic regurgitation (AR) are described below and summarized in the table  (
         <a class="graphic graphic_table graphicRef108959" href="/z/d/graphic/108959.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3561500091">
         <span class="h2">
          Heart rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to the management of patients with aortic or mitral stenosis (MS), maintain a normal to fast heart rate (HR) of 80 to 95 beats per minute (bpm) in patients with AR. A faster HR limits the duration of diastole when aortic valvular regurgitation is occurring; thus, regurgitant volume is reduced.
        </p>
        <p>
         Avoid bradycardia because this increases the regurgitant fraction. A slow HR associated with hypotension is treated with bolus doses of
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         5 to 10 mg.
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         0.4 mg may also be administered and/or a low-dose infusion of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         may be initiated  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H4205030504">
         <span class="h2">
          Heart rhythm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although sinus rhythm (SR) is preferred, supraventricular tachyarrhythmia (SVT) will be better tolerated in patients with AR than in those with aortic stenosis (AS) or MS. However, if hemodynamic instability develops and HR cannot be controlled pharmacologically, synchronized cardioversion is used to restore SR.
        </p>
        <p class="headingAnchor" id="H1850752475">
         <span class="h2">
          Afterload (systemic vascular resistance)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevent significant increases in systemic vascular resistance (SVR) by maintaining a low to normal systolic blood pressure (BP) of approximately 100 to 120 mmHg, or within 20 percent of baseline. Maintaining a low SVR enhances forward flow during systole and may reduce the regurgitant fraction.
        </p>
        <p>
         Mild hypotension is typically well tolerated in patients with AR. However, the pulse pressure may be large and diastolic BP may be very low; therefore, we typically follow mean arterial pressure (MAP) as well as systolic BP. Significant hypotension or a very low diastolic BP in patients with concomitant coronary artery disease is treated with bolus doses of an agent that increases contractility (eg,
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         ).
        </p>
        <p>
         Avoid and promptly treat hypertension since increased SVR increases regurgitant flow and decreases forward flow. Elevations in MAP are prevented by ensuring continuation of chronically administered antihypertensive medications, adequate depth of intraoperative anesthesia, and effective postoperative analgesia. If necessary, a vasodilator (eg, calcium channel blocker,
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         ) may be infused to decrease MAP and SVR  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2464836596">
         <span class="h2">
          Preload (intravascular volume)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintain preload while attempting to avoid excessive volume administration. The goal is to maintain adequate intravascular volume without precipitating fluid overload and pulmonary congestion. In patients with preexisting heart failure, a restrictive (zero balance) fluid strategy is typically employed. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management", section on 'Restrictive (zero-balance) strategy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H493620808">
         <span class="h2">
          Contractility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avoid doses of drugs that might cause significant depression of myocardial contractility (eg, high doses of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or volatile anesthetic agents).
        </p>
        <p>
         If necessary to treat hypotension in a patient with severe chronic AR and heart failure, continuous infusion of an inodilator that increase stroke volume (SV) via a combination of peripheral dilation and enhanced contractility is typically selected (eg, a phosphodiesterase inhibitor such as
         <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">
          milrinone
         </a>
         and/or a beta adrenergic inotropic agent such as
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         )  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         ). In some patients, addition or substitution of a low-dose
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         infusion may be necessary to maintain adequate BP.
        </p>
        <p class="headingAnchor" id="H707535865">
         <span class="h1">
          MITRAL REGURGITATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Key points for perioperative hemodynamic management of patients with primary mitral regurgitation (MR) are similar to those for aortic regurgitation (AR)  (
         <a class="graphic graphic_table graphicRef108959" href="/z/d/graphic/108959.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p>
         Hemodynamic considerations are somewhat different for patients with secondary MR due to ischemic heart disease or nonischemic heart disease (dilated cardiomyopathy), as described below and in the table  (
         <a class="graphic graphic_table graphicRef128551" href="/z/d/graphic/128551.html" rel="external">
          table 9
         </a>
         ).
        </p>
        <p>
         Hemodynamic considerations for patients with MR secondary to hypertrophic cardiomyopathy with systolic anterior motion of the mitral valve leaflets are discussed in a separate topic  (
         <a class="graphic graphic_table graphicRef109934" href="/z/d/graphic/109934.html" rel="external">
          table 10
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/114418.html" rel="external">
          "Anesthesia for patients with hypertrophic cardiomyopathy undergoing noncardiac surgery", section on 'Hemodynamic goals and management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2636136072">
         <span class="h2">
          Heart rate
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary MR
         </strong>
         – For patients with primary MR, maintain a normal to fast heart rate (HR) of 80 to 95 beats per minute (bpm) to reduce regurgitation into the left atrium (LA) during systole. However, excessive tachycardia (eg, due to poorly controlled ventricular rate in a patient with atrial fibrillation [AF]) is avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Avoid bradycardia. Bradycardia associated with hypotension is treated with bolus doses of
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         5 to 10 mg. If ineffective,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         0.4 mg may be administered, and a low-dose infusion of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         may be initiated  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">
          "Arrhythmias during anesthesia", section on 'Sinus bradycardia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary MR
         </strong>
         – For patients with secondary MR due to ischemic heart disease, a slower HR of 55 to 80 bpm is generally optimal to reduce the risk of provoking ischemia  (
         <a class="graphic graphic_table graphicRef91907" href="/z/d/graphic/91907.html" rel="external">
          table 3
         </a>
         ), while those with secondary MR due to heart failure with reduced ejection fraction may have a lower HR due to preoperative treatment with a beta blocker and/or renin-angiotensin system blocker  (
         <a class="graphic graphic_table graphicRef128551" href="/z/d/graphic/128551.html" rel="external">
          table 9
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dynamic secondary MR associated with hypertrophic cardiomyopathy accompanied by left ventricular (LV) outflow tract obstruction is summarized in the table  (
         <a class="graphic graphic_table graphicRef109934" href="/z/d/graphic/109934.html" rel="external">
          table 10
         </a>
         ), and is discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/114418.html" rel="external">
          "Anesthesia for patients with hypertrophic cardiomyopathy undergoing noncardiac surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1372030109">
         <span class="h2">
          Heart rhythm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although sinus rhythm (SR) is preferred, many patients with chronic primary MR have AF because of dilation of the LA. A supraventricular tachyarrhythmia (SVT) such as AF will be better tolerated in patients with primary MR than in those with aortic stenosis (AS) or mitral stenosis (MS). However, sudden onset of SVT with a rapid ventricular response may result in hemodynamic instability requiring pharmacologic rate control or cardioversion.
        </p>
        <p class="headingAnchor" id="H687260699">
         <span class="h2">
          Afterload (systemic vascular resistance)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Control of hypertension is important in patients with MR as elevated blood pressure (BP) may worsen regurgitant flow into the LA and decrease cardiac output (CO). Prevention and treatment of hypertension are similar to management of patients with AR. (See
         <a class="local">
          'Afterload (systemic vascular resistance)'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary MR
         </strong>
         – Prevent significant increases in systemic vascular resistance (SVR) by maintaining a low to normal systolic BP of approximately 100 to 120 mmHg, or within 20 percent of baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary MR
         </strong>
         – For patients with secondary MR, management of BP is particularly challenging. Adequate BP is necessary to maintain adequate coronary perfusion pressure and myocardial oxygen supply during diastole  (
         <a class="graphic graphic_table graphicRef91907" href="/z/d/graphic/91907.html" rel="external">
          table 3
         </a>
         ). However, acute increases in systolic BP are avoided or treated since these may increase regurgitant flow into the LA and decrease forward flow, and may also increase myocardial oxygen demand. A reasonable approach is to maintain systemic BP close to preoperative values throughout the perioperative period. (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If necessary to treat hypotension in a patient with chronic severe MR and associated reduced LV ejection fraction, continuous infusion of an inodilator such as
         <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">
          milrinone
         </a>
         and/or a beta adrenergic inotropic agent such as
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         is reasonable  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         ). Addition or substitution of a low-dose
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         infusion may be necessary to maintain adequate BP in some patients. Pure alpha agonists (eg,
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         ) are generally avoided. Administration of any vasopressor agents is cautious (ie, in small doses or with incremental adjustments), with close monitoring to avoid a sudden increase in afterload and/or bradycardia, which may worsen MR and further reduce CO.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2506394313">
         <span class="h2">
          Preload (intravascular volume)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintain preload while attempting to avoid excess volume administration, similar to management of patients with AR. (See
         <a class="local">
          'Preload (intravascular volume)'
         </a>
         above.)
        </p>
        <p>
         Most patients with primary or secondary MR are receiving chronic diuretic therapy, and may present to the operating room with hypovolemia. Fluid is administered in 100 to 250 mL increments to restore and maintain optimal intravascular volume, with assessment of the hemodynamic response after each increment. Aggressive fluid administration is avoided in order to avoid fluid overload and pulmonary congestion.
        </p>
        <p>
         Conversely, some patients with primary or secondary MR present to the operating room with hypervolemia and pulmonary congestion. In these cases, an intravenous (IV)
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         infusion  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ) and/or diuretic administration (eg,
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         10 to 20 mg) may be beneficial to reduce preload. Nitroglycerin may be particularly useful in patients with ischemic MR and evidence of hypervolemia and pulmonary congestion.
        </p>
        <p class="headingAnchor" id="H2961671492">
         <span class="h2">
          Contractility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avoid doses of drugs that might cause significant depression of myocardial contractility (eg, high doses of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or volatile anesthetic agents).
        </p>
        <p>
         Similar to patients with AR, if continuous infusion of an inotropic agent is necessary for a patient with MR and severe ventricular systolic dysfunction, an inodilator such as
         <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">
          milrinone
         </a>
         or
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         is typically selected  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 5
         </a>
         ) (see
         <a class="local">
          'Contractility'
         </a>
         above). Occasionally, infusion of low-dose
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         may be necessary to treat hypotension in patients with primary or secondary MR .
        </p>
        <p class="headingAnchor" id="H1362171273">
         <span class="h2">
          Pulmonary vascular resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avoid hypoxemia, hypercarbia, and metabolic acidosis, which further increase pulmonary vascular resistance (PVR), and exacerbate pre-existing pulmonary hypertension (PH).
        </p>
        <p class="headingAnchor" id="H1057284168">
         <span class="h1">
          COMBINATIONS OF VALVE LESIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although each cardiac valve lesion is assessed individually, patients may have a combination of stenosis and regurgitation in a single cardiac valve, or stenosis or regurgitation of two separate valves [
         <a href="#rid10">
          10
         </a>
         ]. Optimal management depends on which of the valvular lesions is predominant and which hemodynamic changes are likely to be most deleterious  (
         <a class="graphic graphic_table graphicRef109935" href="/z/d/graphic/109935.html" rel="external">
          table 11
         </a>
         ). Anesthetic techniques, agents, and vasoactive drugs are selected to achieve appropriate hemodynamic goals. A reasonable approach for a patient who is hemodynamically stable and compensated in the preoperative period is to target preoperative heart rate (HR) and blood pressure (BP) values as a goal during surgery.
        </p>
        <p>
         Common combinations of valvular lesions include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aortic stenosis with aortic regurgitation
         </strong>
         – Concurrent aortic regurgitation (AR) is present in many patients with aortic stenosis (AS), but is usually mild (see
         <a class="medical medical_review" href="/z/d/html/8164.html" rel="external">
          "Clinical manifestations and diagnosis of aortic stenosis in adults", section on 'Diagnostic echocardiography'
         </a>
         ). Typically, a HR target in the normal range of 70 to 80 beats per minute (bpm) is optimal for such patients, rather than a relatively fast or slow HR. Preload, afterload (systemic vascular resistance [SVR]), and contractility are also maintained within normal ranges.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mitral stenosis with mitral regurgitation
         </strong>
         – The combination of mitral stenosis (MS) and mitral regurgitation (MR) is common [
         <a href="#rid11">
          11
         </a>
         ]. Hemodynamic targets for such patients take the differing requirements for each lesion into consideration  (
         <a class="graphic graphic_table graphicRef108960" href="/z/d/graphic/108960.html" rel="external">
          table 7
         </a>
         and
         <a class="graphic graphic_table graphicRef108959" href="/z/d/graphic/108959.html" rel="external">
          table 8
         </a>
         ). Typically, a normal HR (eg, 70 to 80 bpm), normal or low to normal SVR, and normal contractility are optimal [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4094254781">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115482.html" rel="external">
          "Society guideline links: Cardiac valve disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3688150710">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Key points for selected valve lesions
         </strong>
         – Key points for perioperative hemodynamic management of patients with aortic or mitral valve disease are summarized in the tables  (
         <a class="graphic graphic_figure graphicRef108930" href="/z/d/graphic/108930.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Aortic stenosis (AS)
         </strong>
         (
         <a class="graphic graphic_table graphicRef108941" href="/z/d/graphic/108941.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mitral stenosis (MS)
         </strong>
         (
         <a class="graphic graphic_table graphicRef108960" href="/z/d/graphic/108960.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Aortic regurgitation (AR)
         </strong>
         (
         <a class="graphic graphic_table graphicRef108959" href="/z/d/graphic/108959.html" rel="external">
          table 8
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mitral regurgitation (MR)
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Primary MR
         </strong>
         (
         <a class="graphic graphic_table graphicRef108959" href="/z/d/graphic/108959.html" rel="external">
          table 8
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Secondary MR
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Secondary MR associated with ischemic heart disease  (
         <a class="graphic graphic_table graphicRef91907" href="/z/d/graphic/91907.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Secondary MR associated with dilated cardiomyopathy  (
         <a class="graphic graphic_table graphicRef128551" href="/z/d/graphic/128551.html" rel="external">
          table 9
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Secondary MR associated with hypertrophic cardiomyopathy  (
         <a class="graphic graphic_table graphicRef109934" href="/z/d/graphic/109934.html" rel="external">
          table 10
         </a>
         ) (See
         <a class="medical medical_review" href="/z/d/html/114418.html" rel="external">
          "Anesthesia for patients with hypertrophic cardiomyopathy undergoing noncardiac surgery", section on 'Hemodynamic goals and management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combined valve lesions
         </strong>
         – Although each cardiac valve lesion is assessed individually, patients may have a combination of stenosis and regurgitation in a single cardiac valve, or disease of more than one valve. Optimal management of anesthetic techniques, agents, and vasoactive drugs depends on which of the valvular lesions is predominant and which hemodynamic changes are likely to be most deleterious  (
         <a class="graphic graphic_table graphicRef109935" href="/z/d/graphic/109935.html" rel="external">
          table 11
         </a>
         ). (See
         <a class="local">
          'Combinations of valve lesions'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tashiro T, Pislaru SV, Blustin JM, et al. Perioperative risk of major non-cardiac surgery in patients with severe aortic stenosis: a reappraisal in contemporary practice. Eur Heart J 2014; 35:2372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sosis M, Cooper PS, Herr G. The diagnosis of "junctional rhythms" with halogenated anesthetics. Anesthesiology 1985; 63:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethna DH, Deboer GE, Millar RA. Observations on 'junctional rhythms' during anaesthesia. Br J Anaesth 1984; 56:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill RF. Treatment of isorhythmic A-V dissociation during general anesthesia with propranolol. Anesthesiology 1989; 70:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujiwara Y, Asakura Y, Shibata Y, et al. A marked decrease in heart rate variability associated with junctional rhythm during anesthesia with sevoflurane and fentanyl. Acta Anaesthesiol Scand 2006; 50:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen K, Thomsen PE, Bagger JP. HV interval in calcific aortic stenosis. Relation to left ventricular function and effect of valve replacement. Br Heart J 1984; 52:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross J Jr. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. J Am Coll Cardiol 1985; 5:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zile MR, Gaasch WH. Heart failure in aortic stenosis - improving diagnosis and treatment. N Engl J Med 2003; 348:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 2021; 162:e183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurup V, Haddadin AS. Valvular heart diseases. Anesthesiol Clin 2006; 24:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frogel J, Galusca D. Anesthetic considerations for patients with advanced valvular heart disease undergoing noncardiac surgery. Anesthesiol Clin 2010; 28:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mittnacht AJ, Fanshawe M, Konstadt S. Anesthetic considerations in the patient with valvular heart disease undergoing noncardiac surgery. Semin Cardiothorac Vasc Anesth 2008; 12:33.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 126622 Version 7.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24553722" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Perioperative risk of major non-cardiac surgery in patients with severe aortic stenosis: a reappraisal in contemporary practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4025882" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The diagnosis of "junctional rhythms" with halogenated anesthetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6743457" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Observations on 'junctional rhythms' during anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2912295" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Treatment of isorhythmic A-V dissociation during general anesthesia with propranolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16548866" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A marked decrease in heart rate variability associated with junctional rhythm during anesthesia with sevoflurane and fentanyl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6743426" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : HV interval in calcific aortic stenosis. Relation to left ventricular function and effect of valve replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24603191" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3882814" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12724478" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Heart failure in aortic stenosis - improving diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33972115" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17240603" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Valvular heart diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20400041" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Anesthetic considerations for patients with advanced valvular heart disease undergoing noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18397904" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Anesthetic considerations in the patient with valvular heart disease undergoing noncardiac surgery.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
